News | July 19, 2023
PrecisionLife identifies first detailed genetic risk factors for long COVID
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Advances clinical research capabilities with leading regulatory grade registries platform
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Subscribe To Our Newsletter & Stay Updated
